Acorah Software Products - Accounts Production 15.0.600 false true 31 January 2023 1 February 2022 false true No description of principal activity 1 February 2023 31 January 2024 31 January 2024 07207119 A Alexandroff A Alexandroff A Jackson A Tikhonov iso4217:GBP iso4217:EUR iso4217:USD xbrli:shares xbrli:pure xbrli:pure 07207119 2023-01-31 07207119 2024-01-31 07207119 2023-02-01 2024-01-31 07207119 frs-core:CurrentFinancialInstruments 2024-01-31 07207119 frs-bus:PrivateLimitedCompanyLtd 2023-02-01 2024-01-31 07207119 frs-bus:FilletedAccounts 2023-02-01 2024-01-31 07207119 frs-bus:Micro-entities 2023-02-01 2024-01-31 07207119 frs-bus:AuditExempt-NoAccountantsReport 2023-02-01 2024-01-31 07207119 frs-bus:Director1 2023-02-01 2024-01-31 07207119 frs-bus:Director2 2023-02-01 2024-01-31 07207119 frs-bus:Director3 2023-02-01 2024-01-31 07207119 frs-bus:Director4 2023-02-01 2024-01-31 07207119 2022-01-31 07207119 2023-01-31 07207119 2022-02-01 2023-01-31 07207119 frs-core:CurrentFinancialInstruments 2023-01-31
Registered number: 07207119
X-Biocell Ltd
Unaudited Financial Statements
For The Year Ended 31 January 2024
TaxAssist Accountants
Balance Sheet
Registered number: 07207119
2024 2023
£ £
Current assets 657 1,033
Prepayments and accrued income 90 90
Creditors: Amounts Falling Due Within One Year (51,355 ) (49,355 )
NET CURRENT LIABILITIES (50,608 ) (48,232 )
TOTAL ASSETS LESS CURRENT LIABILITIES (50,608 ) (48,232 )
NET LIABILITIES (50,608 ) (48,232 )
CAPITAL AND RESERVES (50,608 ) (48,232 )

Notes

1. General Information
X-Biocell Ltd is a private company, limited by shares, incorporated in England & Wales, registered number 07207119 . The registered office is 208 Mill Road, Cambridge, CB1 3NF.
2. Average Number of Employees
Average number of employees, including directors, during the year was: 4 (2023: 5)
4 5
3. Other Commitments
Included in other creditors is the amount of £11,500 owed to Anton Alexandroff and £7,100 owed to Andrey Tikhonov. Included in trade creditors is an amount of £7,619 which is owed to Group Bruzell Ltd which is payment for R&D Tax Credit related work and for general corporate advice, the payments will be made in the following form: the net amount in shares of X-Biocell Limited and this will be executed when convenient but prior to the next major capital increase. The conversion will be done at the price paid at the most recent capital increase which was £6,301.37 per share. The share certificates will be issued in the name of Group Bruzell Ltd or any other limited company as instructed by Group Bruzell Ltd.
For the year ending 31 January 2024 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.
The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.
The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.
These accounts have been prepared in accordance with the micro-entity provisions and delivered in accordance with the provisions applicable to companies subject to the small companies' regime.
On behalf of the board
A Alexandroff
Director
9 August 2024